The North America endometriosis market was valued at USD 800.87 Million in 2025 and is expected to grow at a CAGR of 10.10%, reaching USD 2096.21 Million by 2035. The market growth is driven by growing awareness of endometriosis, advancements in diagnostic tools, and rising demand for targeted therapies.
Base Year
Historical Period
Forecast Period
In the United States, around 6.5 million women are reported to suffer from endometriosis. This rising burden of the disease is expected to directly impact the market demand for effective treatment options and advanced diagnostic methods.
One of the major North America endometriosis market trends is the rise in merger and acquisition activities. For example, in January 2024, Hera Biotech, Inc., acquired Scailyte AG to expedite the development of non-invasive clinical diagnostic tests for endometriosis.
Increased research funding for endometriosis and heightened patient awareness are influencing the market share.
Compound Annual Growth Rate
10.1%
Value in USD Million
2026-2035
*this image is indicative*
Endometriosis is an inflammatory chronic pain condition characterized by the growth of uterine tissue outside the uterus, leading to severe pain in the pelvis, fertility issues, and the formation of scar tissue primarily in the pelvis region. The gold standard for endometriosis diagnosis is laparoscopic surgery. The invasive nature of the diagnosis method results in an almost eight-year average delay until a proper diagnosis is given. This has prompted many companies to invest in the development of minimally invasive diagnostic solutions. Moreover, the advancement in healthcare infrastructure and the rising healthcare expenditure are contributing to the expansion of the global endometriosis treatment market. Further, there is a growing emphasis on women’s health issues, leading to substantial research funding for the field, which is projected to fuel the North America endometriosis market growth.
According to the World Health Organisation, 190 million women and girls of reproductive age (which accounts for roughly 10% of the population) are affected by endometriosis. In the United States, around 6.5 million women are reported to suffer from the condition. The rising burden of endometriosis will augment the demand for effective treatment options and advanced diagnostic methods, which is likely to bolster the market growth. Further, the growing awareness campaigns and educational initiatives are leading to increased diagnoses of the disease, which is expected to boost the North America endometriosis market share in the forecast period.
One of the major market trends is the rise in merger and acquisition activities to accelerate the development of new treatments and diagnostic tools for endometriosis. In January 2024, Hera Biotech, Inc. (a Texas-based biotechnology company developing tissue-based tests designed to diagnose and stage endometriosis) acquired Scailyte AG (a Swiss company specializing in single-cell omics and Al-fueled biomarker discovery), marking a major endometriosis diagnostic market consolidation event of the only two tissue-based diagnostic programs for endometriosis. The acquisition aims to leverage the companies’ extensive research on tissue-based biomarkers and speed up the development of highly accurate, non-invasive clinical diagnostic tools. Such strategic partnerships are likely to expedite the introduction and commercialization of non-invasive diagnostic tests for endometriosis and are poised to elevate the market value in coming years.
The EMR’s report titled “North America Endometriosis Market Report and Forecast 2026-2035” offers a detailed analysis of the market based on the following segments:
Market Breakup by Drug
Market Breakup by Type
Market Breakup by Treatment Type
Market Breakup by End User
Market Breakup by Distribution Channel
Market Breakup by Region
The key features of the market report include patent analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
This American multinational healthcare company is known for its drug Elagolix (the first oral gonadotropin-releasing hormone antagonist that entered clinical development and was granted regulatory approval to manage endometriosis), developed in collaboration with an American biopharmaceutical company Neurocrine Biosciences, Inc.
Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company specializing primarily in generic drugs. It has a robust generic women’s health portfolio and invests heavily in pharmaceutical products aimed at improving women's reproductive health.
Sun Pharma is a prominent global specialty generic pharmaceutical company. The company sells Leuprolide injection (Lupron Depot) which is used alone or in combination with other drugs such as norethindrone to treat endometriosis.
Sanofi S.A. is a French multinational pharmaceutical and healthcare company. Its drug asset Danazol is a pituitary gonadotropin inhibitor used in the treatment of endometriosis.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other players in the market include AbbVie, Inc., AstraZeneca PLC, Pfizer, Inc., Merck & Co., Inc., GlaxoSmithKline PLC, and Consilient Health Limited.
Upto 15% Off
USD
$4299 $3869
$2699 $2429
$5799 $4949
$6999 $5949
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The market is anticipated to grow at a CAGR of 10.10% during the forecast period of 2026-2035, driven by the increasing prevalence of endometriosis in the region.
The rising investment in endometriosis research and advancements in diagnostic technologies are fuelling the demand for the market.
One of the significant trends in the market is the rise in strategic partnerships among the key players. For example, in January 2024 , Hera Biotech, Inc., acquired Scailyte AG to expedite the development of non-invasive clinical diagnostic tests for endometriosis.
Based on the drug, the market is segmented into oral contraceptives, progestins, NSAIDS, GnRH analogues, and LNR-IUDs, among others.
By type, the market is divided into superficial peritoneal endometriosis, endometriomas, and deeply infiltrating endometriosis, among others.
The market breakup by treatment type includes hormonal therapy, and pain management, among others.
End users of the market are hospitals and specialty clinics, among others.
Major distribution channels of the market include hospital pharmacies, retail pharmacies, drugstores, and E-commerce, among others.
The market segmentation by countries includes the United States of America and Canada.
The key players in the market are Abbott Laboratories, Teva Pharmaceuticals Industries Ltd., Sun Pharmaceutical Industries Ltd., Sanofi S.A., AbbVie, Inc., AstraZeneca PLC, Pfizer, Inc., Merck & Co., Inc., GlaxoSmithKline PLC, and Consilient Health Limited.
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug |
|
| Breakup by Type |
|
| Breakup by Treatment Type |
|
| Breakup by End User |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Single User License
One User
USD 4,299
USD 3,869
tax inclusive*
Datasheet
One User
USD 2,699
USD 2,429
tax inclusive*
Five User License
Five User
USD 5,799
USD 4,949
tax inclusive*
Corporate License
Unlimited Users
USD 6,999
USD 5,949
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share